AVXL Quote, Financials, Valuation and Earnings

ADMA Biologics, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of 27.14%. Anavex Life Sciences Corp.'s return on equity of -44.87% beat ADMA Biologics, Inc.'s return on equity of 58.71%.

Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 394.38%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $27.25 which suggests that it could grow by 35.51%. Given that Anavex Life Sciences Corp. has higher upside potential than ADMA Biologics, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than ADMA Biologics, Inc..

Anavex Life Sciences Corp. has a beta of 1.155, which suggesting that the stock is 15.531% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.

Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.

Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Anavex Life Sciences Corp.'s net income of -$9.8M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 23.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus 10.12x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Aldeyra Therapeutics, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of --. Anavex Life Sciences Corp.'s return on equity of -44.87% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.

Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 394.38%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 98.09%. Given that Anavex Life Sciences Corp. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Aldeyra Therapeutics, Inc..

Anavex Life Sciences Corp. has a beta of 1.155, which suggesting that the stock is 15.531% more volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.

Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.

Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than Aldeyra Therapeutics, Inc. quarterly revenues of --. Anavex Life Sciences Corp.'s net income of -$9.8M is lower than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CorMedix, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of 49.9%. Anavex Life Sciences Corp.'s return on equity of -44.87% beat CorMedix, Inc.'s return on equity of 95.25%.

Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 394.38%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 78.57%. Given that Anavex Life Sciences Corp. has higher upside potential than CorMedix, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than CorMedix, Inc..

Anavex Life Sciences Corp. has a beta of 1.155, which suggesting that the stock is 15.531% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.

Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Anavex Life Sciences Corp.'s net income of -$9.8M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus 3.58x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of -40.15%. Anavex Life Sciences Corp.'s return on equity of -44.87% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 394.38%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 122.96%. Given that Anavex Life Sciences Corp. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Vanda Pharmaceuticals, Inc..

Anavex Life Sciences Corp. has a beta of 1.155, which suggesting that the stock is 15.531% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Anavex Life Sciences Corp.'s net income of -$9.8M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus 1.46x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.